• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA approves trial expansion for dual-optic accommodating IOL


Irvine, CA-Visiogen Inc. has received FDA approval to expand the phase III clinical trial of its dual-optic accommodating IOL (Synchrony) in the United States.

Irvine, CA-Visiogen Inc. has received FDA approval to expand the phase III clinical trial of its dual-optic accommodating IOL (Synchrony) in the United States.

The single-piece silicone lens is being evaluated for safety, effectiveness, and the potential to correct near and intermediate vision without the use of spectacles in patients after cataract surgery. The lens already is approved for use throughout the European Union.

“Full expansion of the clinical trial for [the IOL] is another significant step toward our ultimate goal of approval for use within the United States,” according to Barbara Niksch, vice president of regulatory, quality, and clinical affairs at Visiogen.

The lens unfolds in the eye on insertion via a preloaded injector through a 3.6- to 3.8-mm clear corneal incision. A spring system connects the two optics, a 5.5-mm high-power anterior optic and a 6-mm negative-power posterior optic. The spring action moves the front optic and changes the eye’s focus from near to far. The combination of positive- and negative-powered optics is customized for each patient.

The IOL has been implanted in more than 400 patients worldwide. The company received the European CE mark for the lens in June, allowing the company to expand into post-marketing research studies within Europe.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.